^
    6ms
    Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies. (PubMed, J Immunother Cancer)
    IMSA101 doses of 1,200 µg (monotherapy arm) and 2,400 µg (combination therapy arm) were well tolerated but demonstrated minimal signals of antitumor activity in patients with advanced solid tumors.
    P1 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    IMSA101
    8ms
    SPARK: Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=15, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • IMSA101
    12ms
    Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov)
    P2, N=16, Terminated, ImmuneSensor Therapeutics Inc. | N=51 --> 16 | Trial completion date: Feb 2026 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Nov 2024; Change in ImmuneSensor corporate strategy
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    1year
    A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, ImmuneSensor Therapeutics Inc. | Phase classification: P1/2 --> P1 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    IMSA101
    1year
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, ImmuneSensor Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    1year
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC (clinicaltrials.gov)
    P2, N=6, Terminated, ImmuneSensor Therapeutics Inc. | N=46 --> 6 | Trial completion date: Feb 2026 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Sep 2024; Slow enrollment.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    1year
    SPARK: Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University of Texas Southwestern Medical Center
    New P2 trial • Combination therapy • Checkpoint inhibition • Metastases
    |
    Opdivo (nivolumab) • IMSA101
    over1year
    The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. (PubMed, Nat Commun)
    Consistent with this, the use of IL-18 receptor negative CART impair anti-tumor responses in mice receiving combination treatment. In summary, we find that IMSA101 enhances CART function which is facilitated through STING agonist-induced IL-18 secretion.
    Journal • CAR T-Cell Therapy
    |
    STING (stimulator of interferon response cGAMP interactor 1) • IL18 (Interleukin 18)
    |
    IL18 elevation
    |
    IMSA101
    2years
    A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (clinicaltrials.gov)
    P1/2, N=2, Active, not recruiting, ImmuneSensor Therapeutics Inc. | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    IMSA101
    2years
    Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov)
    P1/2, N=40, Completed, ImmuneSensor Therapeutics Inc. | Recruiting --> Completed | N=115 --> 40 | Trial completion date: Dec 2023 --> Sep 2023
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    HR negative
    |
    IMSA101
    over2years
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov)
    P2, N=51, Recruiting, ImmuneSensor Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    over2years
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC (clinicaltrials.gov)
    P2, N=46, Recruiting, ImmuneSensor Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101